Nab-paclitaxel (Abraxane)-based chemotherapy to treat elderly patients with advanced non-small-cell lung cancer: A single center, randomized and open-label clinical trial

Chinese Journal of Cancer Research

Volumn 27, Issue 2, 2015, Pages 190-196

  Chen, Hanrui ^a   Huang, Xuewu ^a   Wang, Shutang ^a   Zheng, Xinting ^a   Lin, Jietao ^a   Li, Peng ^a   Lin, Lizhu ^a  

^a GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Advanced non small cell lung cancer (NSCLC); Efficacy; Elderly; Nab paclitaxel; Pretreated

Indexed keywords

NEDAPLATIN; PACLITAXEL;

ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; MALE; MYALGIA; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA;

EID: 84940213627     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.3978/j.issn.1000-9604.2014.12.17     Document Type: Article

References (21)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Vamvakas L, Saloustros E, Karampeazis A, et al. Advanced non-small-cell lung cancer in the elderly. Clin Lung Cancer 2009;10:158-67.
3. NCCN Clinical Practice Guidelines in Oncology. Lung Cancer Screening version 1, 2013. Available online: http://www. respiratory-thessaly.gr/assets/lung_screening%201.2013.pdf
4. Green MR, Manikhas GM, Orlov S, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006;17:1263-8.
5. Edge SB, Byrd DR, Compton CC, et al. eds. AJCC Cancer Staging Manual 7th Edition. New York: Springer, 2010:253-70.
6. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
7. Tang Y, Wang W, Teng XZ, et al. Efficacy of S-1 plus nedaplatin compared to standard second-line chemotherapy in EGFR-negative lung adenocarcinoma after failure of first-line chemotherapy. Tumour Biol 2014;35:8945-51.
8. Li CH, Liu MY, Liu W, et al. Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer. Asian Pac J Cancer Prev 2014;15:731-6.
9. Fidias P, Supko JG, Martins R, et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res 2001;7:3942-9.
10. Rossi D, Dennetta D, Ugolini M, et al. Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study. Clin Lung Cancer 2008;9:280-4.
11. Bauman JE, Eaton KD, Wallace SG, et al. A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer. BMC Cancer 2012;12:449.
12. Okamoto I, Moriyama E, Fujii S, et al. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 2005;35:188-94.
13. Giorgio CG, Pappalardo A, Russo A, et al. A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer 2006;51:357-62.
14. Ramalingam S, Perry MC, La Rocca RV, et al. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer. Cancer 2008;113:542-6.
15. Sakakibara T, Inoue A, Sugawara S, et al. Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer. Ann Oncol 2010;21:795-9.
16. Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590-8.
17. Uziely B, Jeffers S, Muggia F. Low doses of dexamethasone protect against paclitaxel (Taxol)-related hypersensitivity reactions following cycle 1. Ann Oncol 1994;5:474.
18. Rizvi NA, Riely GJ, Azzoli CG, et al. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol 2008;26:639-43.
19. Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012;30:2055-62.
20. John TA, Vogel SM, Tiruppathi C, et al. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol 2003;284:L187-96.
21. Schiemann BJ, Neil JR, Schiemann WP. SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Mol Biol Cell 2003;14:3977-88.